CIDNAVIR Injection 75 mg/mL (Cidofovir): Product Information for Singapore

CIDNAVIR Injection 75 mg/mL is identified as a cidofovir-containing injectable medicine. Cidofovir is an antiviral agent that belongs to the nucleotide analogue class of medicines. It interferes with viral DNA synthesis and is used in specific clinical circumstances under specialist medical supervision.

The product name, formulation, manufacturer, approved indications and registration status should be verified against the manufacturer's official product documentation before publication or supply in Singapore.

Active Ingredient and Strength

Brand name: CIDNAVIR

Active ingredient: Cidofovir

Strength: 75 mg/mL

Dosage form: Injection

Therapeutic category: Antiviral medicine

Route of administration: Intravenous administration for approved cidofovir formulations, as directed by the relevant product information.

The stated strength of 75 mg/mL represents the concentration of cidofovir in the solution. It should not be confused with the total amount of medicine contained in a vial. Pack size, excipients, storage conditions and shelf life must be confirmed using the manufacturer's approved documentation.

Clinical Uses and Pharmacological Benefits

Cidofovir inhibits viral DNA replication through its active intracellular metabolites. Its clinical use depends on the virus involved, the patient's condition and the applicable approved product information.

Cidofovir has been used for cytomegalovirus (CMV) retinitis in certain patients with AIDS. However, this historical or established use must not automatically be attributed to CIDNAVIR without confirming the product's approved indications in the relevant jurisdiction.

Potential clinical benefits depend on appropriate patient selection, specialist assessment and adherence to the prescribed treatment protocol. Cidofovir is not suitable for unsupervised use, and its availability does not establish that it is approved for every viral infection.

Important Safety Information and Side Effects

Cidofovir can cause serious adverse reactions and requires careful clinical monitoring. Its most significant safety concern is kidney toxicity, which may lead to substantial renal impairment.

Potential adverse effects include:

Kidney toxicity: Renal impairment, increased serum creatinine and proteinuria.

Blood-related effects: Neutropenia, involving reduced levels of certain white blood cells.

Eye-related effects: Uveitis and reduced intraocular pressure have been reported.

General reactions: Nausea, fever, headache, rash and hair loss may occur.

The nature and frequency of adverse reactions vary according to the patient, treatment regimen and clinical circumstances. Healthcare professionals should consult the applicable prescribing information for contraindications, warnings, drug interactions and required laboratory monitoring.

Cidofovir treatment may require intravenous hydration and probenecid to reduce renal toxicity, according to the applicable prescribing information. Treatment decisions and monitoring must be managed by qualified healthcare professionals.

Frequently Asked Questions

1. What is the active ingredient in CIDNAVIR Injection?

The stated active ingredient is cidofovir, an antiviral nucleotide analogue. Confirm the ingredient and formulation against the manufacturer's official product documentation.

2. What is the strength of CIDNAVIR Injection?

The specified strength is 75 mg/mL. The total quantity per vial depends on the verified vial volume and packaging.

3. What is cidofovir used for?

Cidofovir has established clinical use in specific viral infections, including CMV retinitis in certain patients with AIDS. The approved indication for CIDNAVIR in Singapore must be independently verified.

4. What are the important side effects?

Kidney toxicity is a major concern. Other possible adverse effects include neutropenia, proteinuria, eye inflammation, nausea, fever, headache and rash.

5. Can CIDNAVIR be purchased online in Singapore?

The product's registration and supply eligibility must be confirmed with Singapore's Health Sciences Authority (HSA). Prescription medicines may only be supplied online by appropriately licensed healthcare institutions or pharmacies, subject to applicable requirements.

6. What should pharmaceutical buyers verify?

Healthcare institutions, licensed distributors and authorised pharmaceutical procurement teams should verify product registration, manufacturer details, quality documentation, batch traceability, storage requirements and import authorisations before procurement.

Regulatory and Procurement Notice

This page is intended as factual product information for qualified healthcare professionals and pharmaceutical trade audiences, subject to applicable Singapore advertising restrictions. It is not a substitute for the approved product insert or professional medical advice. CIDNAVIR's Singapore registration status and approved indications have not been independently confirmed.